共查询到20条相似文献,搜索用时 0 毫秒
1.
Michael P. Dwyer Kartik Keertikar Kamil Paruch Carmen Alvarez Marc Labroli Cory Poker Thierry O. Fischmann Rosemary Mayer-Ezell Richard Bond Yan Wang Rita Azevedo Timothy J. Guzi 《Bioorganic & medicinal chemistry letters》2013,23(22):6178-6182
The synthesis and hit-to-lead SAR development from a pyrazolo[1,5-a]pyrimidine-derived hit 5 to the identification of a series of potent, pan–Pim inhibitors such as 11j are described. 相似文献
2.
Dan M. Berger Nancy Torres Minu Dutia Dennis Powell Greg Ciszewski Ariamala Gopalsamy Jeremy I. Levin Kyung-Hee Kim Weixin Xu James Wilhelm YongBo Hu Karen Collins Larry Feldberg Steven Kim Eileen Frommer Donald Wojciechowicz Robert Mallon 《Bioorganic & medicinal chemistry letters》2009,19(23):6519-6523
As part of our research effort to discover B-Raf kinase inhibitors, we prepared a series of C-3 substituted N-(3-(pyrazolo[1,5-a]pyrimidin-7-yl)phenyl)-3-(trifluoromethyl)benzamides. X-ray crystallography studies revealed that one of the more potent inhibitors (10n) bound to B-Raf kinase without forming a hinge-binding hydrogen bond. With basic amine residues appended to C-3 aryl residues, cellular activity and solubility were enhanced over previously described compounds of this class. 相似文献
3.
Saul Jaime-Figueroa Javier De Vicente Johannes Hermann Alam Jahangir Sue Jin Andreas Kuglstatter Stephen M. Lynch John Menke Linghao Niu Vaishali Patel Ada Shao Michael Soth Minh Diem Vu Calvin Yee 《Bioorganic & medicinal chemistry letters》2013,23(9):2522-2526
We report the discovery of a novel series of ATP-competitive Janus kinase 3 (JAK3) inhibitors based on the 5H-pyrrolo[2,3-b]pyrazine scaffold. The initial leads in this series, compounds 1a and 1h, showed promising potencies, but a lack of selectivity against other isoforms in the JAK family. Computational and crystallographic analysis suggested that the phenyl ether moiety possessed a favorable vector to achieve selectivity. Exploration of this vector resulted in the identification of 12b and 12d, as potent JAK3 inhibitors, demonstrating improved JAK family and kinase selectivity. 相似文献
4.
《Bioorganic & medicinal chemistry》2014,22(17):4704-4710
A new series of nitro or amino substituted pyrazolo[4,3-a]phenanthridines was synthesized in 6 steps from 5-bromo-6-nitroindazole. The evaluation of their inhibitory potency toward Pim kinases demonstrated that the nitro series could be considered as an interesting starting point for the development of new Pim kinase inhibitors, especially Pim-3. A preferential binding mode was suggested by molecular modeling experiments for nitro series and Pim-1/Pim-3 ATP-binding sites. Moreover, the most active compounds exhibited antiproliferative activities toward PC3 cells in the micromolar range. 相似文献
5.
Williamson DS Parratt MJ Bower JF Moore JD Richardson CM Dokurno P Cansfield AD Francis GL Hebdon RJ Howes R Jackson PS Lockie AM Murray JB Nunns CL Powles J Robertson A Surgenor AE Torrance CJ 《Bioorganic & medicinal chemistry letters》2005,15(4):863-867
The protein structure guided design of a series of pyrazolo[1,5-a]pyrimidines with high potency for human cyclin-dependent kinase 2 (CDK2) is described. Some examples were shown to inhibit the growth of human colon tumour cells, were equipotent for CDK1 and were selective against GSK-3beta and other kinases. 相似文献
6.
《Bioorganic & medicinal chemistry letters》2020,30(17):127390
Bruton’s tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition, and for the treatment of B cell related diseases. Many BTK inhibitors have been discovered for the treatment of cancer and rheumatoid arthritis, including a series of BTK inhibitors based on 8-amino-imidazo[1,5-a]pyrazine we recently reported. The X-ray crystal structures of BTK with inhibitors were also published, which provided great help for the SAR design. Here we report our SAR work introducing ring constraints for the 3-position piperidine amides on the BTK inhibitors based on 8-amino-imidazo[1,5-a]pyrazine. This modification improved the potency in BTK inhibitions, as well as the PK profile and the off-target selectivity. The dose-dependent efficacy of two BTK inhibitors was observed in the rat collagen induced arthritis (CIA) model. 相似文献
7.
Griffith DA Hargrove DM Maurer TS Blum CA De Lombaert S Inthavongsay JK Klade LE Mack CM Rose CR Sanders MJ Carpino PA 《Bioorganic & medicinal chemistry letters》2011,21(9):2641-2645
A novel series of pyrazolo[1,5-a]pyrimidine derivatives was synthesized and evaluated as NPY Y1R antagonists. High binding affinity and selectivity were achieved with C3 trisubstituted aryl groups and C7 substituted 2-(tetrahydro-2H-pyran-4-ylamino)ethylamine moieties. Efforts to find close analogs with low plasma clearance in the rat and minimal p-glycoprotein efflux in the mouse were unsuccessful. Compound 2f (CP-671906) inhibited NPY-induced increases in blood pressure and food intake after iv and icv administration, respectively, in Sprague-Dawley (SD) rat models. Oral administration of compound 2f resulted in a modest, but statistically significant, reduction in food intake in a Wistar rat model of feeding behavior. Small inhibitions of food intake were also observed in an overnight fasting/refeeding model in SD rats. These data suggest a potential role for Y1R in the regulation of food intake in rodents. 相似文献
8.
Sobhana Babu Boga Abdul-Basit Alhassan Jian Liu Deodial Guiadeen Arto Krikorian Xiaolei Gao James Wang Younong Yu Rajan Anand Shilan Liu Chundao Yang Hao Wu Jiaqiang Cai Hugh Zhu Jagdish Desai Kevin Maloney Ying-Duo Gao Thierry O. Fischmann Joseph A. Kozlowski 《Bioorganic & medicinal chemistry letters》2017,27(16):3939-3943
8-Amino-imidazo[1,5-a]pyrazine-based Bruton’s tyrosine kinase (BTK) inhibitors, such as 6, exhibited potent inhibition of BTK but required improvements in both kinase and hERG selectivity (Liu et al., 2016; Gao et al., 2017). In an effort to maintain the inhibitory activity of these analogs and improve their selectivity profiles, we carried out SAR exploration of groups at the 3-position of pyrazine compound 6. This effort led to the discovery of the morpholine group as an optimized pharmacophore. Compounds 13, 23 and 38 displayed excellent BTK potencies, kinase and hERG selectivities, and pharmacokinetic profiles. 相似文献
9.
Dwyer MP Paruch K Labroli M Alvarez C Keertikar KM Poker C Rossman R Fischmann TO Duca JS Madison V Parry D Davis N Seghezzi W Wiswell D Guzi TJ 《Bioorganic & medicinal chemistry letters》2011,21(1):467-470
The synthesis and hit-to-lead SAR development of a pyrazolo[1,5-a]pyrimidine hit 4 is described leading to a series of potent, selective CHK1 inhibitors such as compound 17r. In the Letter, the further utility of the pyrazolo[1,5-a]pyrimidine template for the development of potent, selective kinase inhibitors is detailed. 相似文献
10.
Ariamala Gopalsamy Greg Ciszewski Mengxiao Shi Dan Berger Yongbo Hu Frederick Lee Larry Feldberg Eileen Frommer Steven Kim Karen Collins Donald Wojciechowicz Robert Mallon 《Bioorganic & medicinal chemistry letters》2009,19(24):6890-6892
Our continued effort towards optimization of the pyrazolo[1,5-a]pyrimidine scaffold as B-Raf kinase inhibitors is described. Structure guided design was utilized to introduce kinase hinge region interacting groups in the 2-position of the scaffold. This strategy led to the identification of lead compound 9 with enhanced enzyme and cellular potency, while maintaining good selectivity over a number of kinases. 相似文献
11.
Labroli M Paruch K Dwyer MP Alvarez C Keertikar K Poker C Rossman R Duca JS Fischmann TO Madison V Parry D Davis N Seghezzi W Wiswell D Guzi TJ 《Bioorganic & medicinal chemistry letters》2011,21(1):471-474
Previous efforts by our group have established pyrazolo[1,5-a]pyrimidine as a viable core for the development of potent and selective CDK inhibitors. As part of an effort to utilize the pyrazolo[1,5-a]pyrimidine core as a template for the design and synthesis of potent and selective kinase inhibitors, we focused on a key regulator in the cell cycle progression, CHK1. Continued SAR development of the pyrazolo[1,5-a]pyrimidine core at the C5 and C6 positions, in conjunction with previously disclosed SAR at the C3 and C7 positions, led to the discovery of potent and selective CHK1 inhibitors. 相似文献
12.
Mark W. Ledeboer Albert C. Pierce John P. Duffy Huai Gao David Messersmith Francesco G. Salituro Suganthini Nanthakumar Jon Come Harmon J. Zuccola Lora Swenson Dina Shlyakter Sudipta Mahajan Thomas Hoock Bin Fan Wan-Jung Tsai Elaine Kolaczkowski Scott Carrier James K. Hogan Richard Zessis S. Pazhanisamy Youssef L. Bennani 《Bioorganic & medicinal chemistry letters》2009,19(23):6529-6533
Constitutive activation of the EPO/JAK2 signaling cascade has recently been implicated in a variety of myeloproliferative disorders including polycythemia vera, essential thrombocythemia and myelofibrosis. In an effort to uncover therapeutic potential of blocking the EPO/JAK2 signaling cascade, we sought to discover selective inhibitors that block the kinase activity of JAK2. Herein, we describe the discovery and structure based optimization of a novel series of 2-amino-pyrazolo[1,5-a]pyrimidines that exhibit potent inhibition of JAK2. 相似文献
13.
Cheung M Harris PA Badiang JG Peckham GE Chamberlain SD Alberti MJ Jung DK Harris SS Bramson NH Epperly AH Stimpson SA Peel MR 《Bioorganic & medicinal chemistry letters》2008,18(20):5428-5430
A series of pyrazolo[1,5-a]pyridine derivatives was designed and synthesized as novel potent p38 kinase inhibitors. Our approaches towards improving in vitro metabolism and in vivo pharmacokinetic properties of the series are described. 相似文献
14.
Isao Sakurada Toshiya Endo Katsuyoshi Hikita Tomokazu Hirabayashi Yoshitaka Hosaka Yutaka Kato Yoshitaka Maeda Shigeki Matsumoto Takashi Mizuno Hiroshi Nagasue Teruyuki Nishimura Shunsuke Shimada Mikihiko Shinozaki Keiko Taguchi Katsutoshi Takeuchi Tooru Yokoyama Alan Hruza Paul Reichert Shoji Furusako 《Bioorganic & medicinal chemistry letters》2017,27(11):2622-2628
Using structure based drug design, novel aminobenzisoxazoles as coagulation factor IXa inhibitors were designed and synthesized. Highly selective inhibition of FIXa over FXa was demonstrated. Anticoagulation profile of selected compounds was evaluated by aPTT and PT tests. In vitro ADMET and pharmacokinetic (PK) profiles were also evaluated. 相似文献
15.
Richardson CM Williamson DS Parratt MJ Borgognoni J Cansfield AD Dokurno P Francis GL Howes R Moore JD Murray JB Robertson A Surgenor AE Torrance CJ 《Bioorganic & medicinal chemistry letters》2006,16(5):1353-1357
Crystallographic and modelling data, in conjunction with a medicinal chemistry template-hopping approach, led to the identification of a series of novel and potent inhibitors of human cyclin-dependent kinase 2 (CDK2), with selectivity over glycogen synthase kinase-3beta (GSK-3beta). One example had a CDK2 IC(50) of 120 nM and showed selectivity over GSK-3beta of 167-fold. 相似文献
16.
Andrii Monastyrskyi Simon Bayle Victor Quereda Wayne Grant Michael Cameron Derek Duckett William Roush 《Bioorganic & medicinal chemistry letters》2018,28(3):400-404
The development of a new series of apoptosis signal-regulating kinase 1 (ASK1) inhibitors is described. Starting from purine, pyrimidine and quinazoline scaffolds identified by high throughput screening, we used tools of structure-based drug design to develop a series of potent kinase inhibitors, including 2-arylquinazoline derivatives 12 and 23, with submicromolar inhibitory activities against ASK1. Kinetic analysis demonstrated that the 2-arylquinazoline scaffold ASK1 inhibitors described herein are ATP competitive. 相似文献
17.
《Bioorganic & medicinal chemistry letters》2014,24(21):4969-4975
The discovery of a novel series of pyrrolopyrazines as JAK inhibitors with comparable enzyme and cellular activity to tofacitinib is described. The series was identified using a scaffold hopping approach aided by structure based drug design using principles of intramolecular hydrogen bonding for conformational restriction and targeting specific pockets for modulating kinase activity. 相似文献
18.
Virginie Suchaud Laurent Gavara Emmanuelle Saugues Lionel Nauton Vincent Théry Fabrice Anizon Pascale Moreau 《Bioorganic & medicinal chemistry》2013,21(14):4102-4111
New 1,6-dihydropyrazolo[4,3-c]carbazoles and 3,6-dihydropyrazolo[3,4-c]carbazoles were prepared and evaluated for their Pim kinase inhibitory potencies as well as their antiproliferative activities toward two prostatic cancer cell lines. Pyrazolocarbazole 15a was found to be a potent Pim kinase modulator with inhibitory potency toward the three isoforms. Compound 6c strongly inhibited Pim-3 with weaker effect toward Pim-1 and Pim-2, and thus could be used as an interesting molecular tool to study Pim-3 biological functions. 相似文献
19.
《Bioorganic & medicinal chemistry letters》2020,30(14):127225
Small molecule JAK inhibitors have been demonstrated efficacy in rheumatoid arthritis, inflammatory bowel disease, and psoriasis with the approval of several drugs. Aiming to develop potent JAK1/2 inhibitors, two series of triazolo [1,5-a] pyridine derivatives were designed and synthesized by various strategies. The pharmacological results identified the optimized compounds J-4 and J-6, which exerted high potency against JAK1/2, and selectivity over JAK3 in enzyme assays. Furthermore, J-4 and J-6 effectively suppressed proliferation of JAK1/2 high-expression BaF3 cells accompanied with acceptable metabolic stability in liver microsomes. Therefore, J-4 and J-6 might serve as promising JAK1/2 inhibitors for further investigation. 相似文献
20.
《Bioorganic & medicinal chemistry letters》2020,30(2):126813
A series of novel 3,6-di-substituted or 3-substituted pyrazolo[1,5-a]pyrimidines were prepared via a microwave-assisted approach that generated a broad array of derivatives in good yields (20–93%, ave. = 59%). The straightforward synthesis involved sequential treatment of commercially-available acetonitrile derivatives with DMF-dimethylacetal (120 °C, 20 min), followed by treatment with NH2NH2·HBr (120 °C, 20 min), and 1,1,3,3-tetramethoxypropane or 2-aryl-substituted malondialdehdyes (120 °C, 20 min). Compounds were screened for antimitotic activities against MCF7 breast cancer and/or A2780 ovarian cancer cell lines in vitro. The most active compounds exhibited EC50 values ranging from 0.5 to 4.3 μM, with the 3-(4-(trifluoromethyl)phenyl)-6-[4-(2-(piperidin-1-yl)ethoxy]phenyl analogue (34e) and the 3-(2-fluorophenyl)-6-[4-(2-(4-methylpiperizin-1-yl)ethoxy]phenyl analogue (35a) being two to three fold more active than Compound C (Dorsomorphin) in A2780 and MCF7 assays, respectively. Importantly, a monosubstituted 3-(benzothiazol-2-yl) derivative (13) was equipotent with the more synthetically challenging 3,6-disubstituted derivatives (34a–e and 35a–e), and exhibited a promising and unique selectivity profile when screened against a panel consisting of 403 protein kinases (Kinomescan™ selectivity score = 0.005, Kd = 0.55 ± 0.055 μM and 0.410 ± 0.20 μM for JAK1 JH2 pseudokinase and VPS34, respectively). 相似文献